GGrantIndex
← Leaderboards

Courtney Fitzhugh

National Heart, Lung, And Blood Institute

$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

By mechanism

Top collaborators

No co-investigators on record.

Most similar at National Heart, Lung, And Blood Institute

Same institution · by research overlap

Others in their field

Top investigators on “Protocols Documentation

Research focus

Protocols DocumentationDoseAcuteSickle Cell AnemiaMorbidity - Disease RateBaseHemoglobinMortalityEnd Stage Renal FailureBone Marrow TransplantationEventEngraftmentChimerismCyclophosphamideFamily MemberCohortAllogenicConditioningGraft RejectionClinical RemissionChronic Graft Versus Host DiseaseBone Marrow PurgingBeta ThalassemiaCirrhosis

Grant awards (13)

Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$3,067,391
ZIA · FY2025 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$3,354,118
ZIA · FY2024 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$1,902,764
ZIA · FY2022 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$1,828,956
ZIA · FY2021 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$1,032,508
ZIA · FY2020 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$1,189,478
ZIA · FY2019 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$1,921,353
ZIA · FY2018 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$1,376,420
ZIA · FY2017 · HL · contact PI
Optimization of Fetal Hemoglobin Production to Prevent or Reverse Organ Damage and Improve Survival in Patients with Sickle Cell Disease$71,164
ZIA · FY2017 · HL · contact PI
Optimization of Fetal Hemoglobin Production to Prevent or Reverse Organ Damage and Improve Survival in Patients with Sickle Cell Disease$2,646,917
ZIA · FY2016 · HL · contact PI
Nonmyeloablative haploidentical peripheral blood stem cell transplantation in congenital anemias$882,306
ZIA · FY2016 · HL · contact PI
Optimization of Fetal Hemoglobin Production to Prevent or Reverse Organ Damage and Improve Survival in Patients with Sickle Cell Disease$3,298,666
ZIA · FY2015 · HL · contact PI
Optimization of Fetal Hemoglobin Production to Prevent or Reverse Organ Damage and Improve Survival in Patients with Sickle Cell Disease$541,648
ZIA · FY2014 · HL · contact PI